Five more biotechs file their SEC pa­per­work as the IPO Class of 2021 swells to 60

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Af­ter last week’s flur­ry of IPO ac­tion end­ed with two pric­ings and a SPAC deal, sev­er­al biotechs got in on the ac­tion be­fore the long hol­i­day week­end.

In ad­di­tion to the two small­er fil­ings that took place on Fri­day, five oth­er biotechs sent their pa­per­work to the SEC. Four of those com­pa­nies — Verve Ther­a­peu­tics, Cen­tu­ry Ther­a­peu­tics, Am­brx Bio­phar­ma and Cyteir Ther­a­peu­tics — have writ­ten in $100 mil­lion as their ini­tial place­hold­er, while HCW Bi­o­log­ics jot­ted down $50 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.